| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004 | 6032 | 2004 |
| Drug penetration in solid tumours AI Minchinton, IF Tannock Nature Reviews Cancer 6 (8), 583-592, 2006 | 2374 | 2006 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 2191 | 2014 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 1943 | 2008 |
| Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. IF Tannock, D Osoba, MR Stockler, DS Ernst, AJ Neville, MJ Moore, ... Journal of Clinical Oncology 14 (6), 1756-1764, 1996 | 1864 | 1996 |
| Acid pH in tumors and its potential for therapeutic exploitation IF Tannock, D Rotin Cancer research 49 (16), 4373-4384, 1989 | 1863 | 1989 |
| Drug resistance and the solid tumor microenvironment O Trédan, CM Galmarini, K Patel, IF Tannock Journal of the National Cancer Institute 99 (19), 1441-1454, 2007 | 1808 | 2007 |
| Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ... JNCI: Journal of the National Cancer Institute 106 (6), 2014 | 1506 | 2014 |
| A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer FR Khuri, J Nemunaitis, I Ganly, J Arseneau, IF Tannock, L Romel, ... Nature medicine 6 (8), 879-885, 2000 | 1299 | 2000 |
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock Journal of Clinical Oncology 26 (2), 242-245, 2008 | 1208 | 2008 |
| Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ... The Lancet 383 (9930), 1721-1730, 2014 | 1140 | 2014 |
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative … PJ Loehrer Sr, LH Einhorn, PJ Elson, ED Crawford, P Kuebler, I Tannock, ... J Clin Oncol 10 (7), 1066-1073, 1992 | 1071 | 1992 |
| The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. IF Tannock British journal of cancer 22 (2), 258, 1968 | 945 | 1968 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 660 | 2011 |
| Repopulation of cancer cells during therapy: an important cause of treatment failure JJ Kim, IF Tannock Nature Reviews Cancer 5 (7), 516-525, 2005 | 643 | 2005 |
| Cognitive function in breast cancer patients receiving adjuvant chemotherapy CB Brezden, KA Phillips, M Abdolell, T Bunston, IF Tannock Journal of Clinical Oncology 18 (14), 2695-2701, 2000 | 632 | 2000 |
| Cytokines and their relationship to the symptoms and outcome of cancer B Seruga, H Zhang, LJ Bernstein, IF Tannock Nature Reviews Cancer 8 (11), 887-899, 2008 | 620 | 2008 |
| Bone metastases: pathophysiology and management policy. OS Nielsen, AJ Munro, IF Tannock Journal of Clinical Oncology 9 (3), 509-524, 1991 | 609 | 1991 |
| The basic science of oncology IF Tannock, RP Hill, RG Bristow, L Harrington Pergamon press, 1987 | 590 | 1987 |
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial … SB Saxman, KJ Propert, LH Einhorn, ED Crawford, I Tannock, ... Journal of Clinical Oncology 15 (7), 2564-2569, 1997 | 557 | 1997 |
